COHEAHR: PUBLICATIONS

List of Published Work

 

 

Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 09;5:CD009069. PMID: 29740819

Berkhof J. The Role of Vaccination in the Prevention of Head and Neck Cancer. In: Vermorken JB, Budach V, Leemans CR, Machiels J-P, Nicolai P, O’Sullivan B, editors. Critical Issues in Head and Neck Oncology: Key Concepts from the Sixth THNO Meeting. Cham: Springer International Publishing; 2018;p. 3-13.

Catarino R, Schäfer S, Vassilakos P, Petignat P, Arbyn M. Accuracy of combinations of visual inspection using acetic acid or lugol iodine to detect cervical precancer: a meta-analysis. BJOG. 2018 Apr;125(5):545-53. PMID: 28603909

Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Sep 1;178(9):1210-22. PMID: 30083701

Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, et al. Eurogin Roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programmes. Int J Cancer. 2018 Jan 17; PMID: 29341110

De Strooper LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, Snijders PJF, Meijer CJLM, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up. Int J Cancer. 2018 Sep 15;143(6):1541-8. PMID: 29663363

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, et al. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. Int J Cancer. 2018 Jul 15;143(2):333-42. PMID: 29453769

Diaz M, Moriña D, Rodríguez-Salés V, Ibáñez R, Espinás JA, de Sanjosé S. Moving towards an organized cervical cancer screening: costs and impact. Eur J Public Health. 2018 Dec 1;28(6):1132-8. PMID: 29684144

Diaz M, de Sanjosé S, Bosch FX, Bruni L. Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. Reports of Practical Oncology & Radiotherapy. 2018 Apr 26.

Eklund C, Forslund O, Wallin K-L, Dillner J. Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies. J Clin Virol. 2018;101:74-85. PMID: 29433017

Faust H, Artemchuk H, Oštrbenk A, Triglav T, Poljak M, Dillner J. Seropositivity to multiple anogenital HPV types is associated with current anogenital HPV infection, abnormal cytology and seropositivity for non-genital HPVs. J Infect Dis. 2018 Sep 7. PMID: 30202984

Gray P, Palmroth J, Luostarinen T, Apter D, Dubin G, Garnett G, et al. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II). Int J Cancer. 2018 Jun 15;142(12):2491-500. PMID: 29377141

Latsuzbaia A, Arbyn M, Dutta S, Fischer M, Gheit T, Tapp J, et al. Complete Genome Sequence of a Novel Human Gammapapillomavirus Isolated from a Cervical Swab in Luxembourg. Genome Announc. 2018 Mar 15;6(11):e00114-18. PMID: 29545294

Latsuzbaia A, Arbyn M, Weyers S, Mossong J. Human papillomavirus vaccination coverage in Luxembourg - Implications of lowering and restricting target age groups. Vaccine. 2018 25;36(18):2411-6. PMID: 29602702

van Leeuwen RW, Oštrbenk A, Poljak M, van der Zee AGJ, Schuuring E, Wisman GBA. DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. Int J Cancer. 2018 Sep 27. PMID: 30259973

Lehtinen M, Luostarinen T, Vänskä S, Söderlund-Strand A, Eriksson T, Natunen K, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J Cancer. 2018 Nov 1;143(9):2299-310. PMID: 29845626

Lehtinen M, Söderlund-Strand A, Vänskä S, Luostarinen T, Eriksson T, Natunen K, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018 01;142(5):949-58. PMID: 29055031

Májek O, Anttila A, Arbyn M, van Veen E-B, Engesæter B, Lönnberg S. The legal framework for European cervical cancer screening programmes. Eur J Public Health 2018 Sep 27. PMID: 30265313

Nyaga V, Arbyn M, Aerts M. Beta-binomial analysis of variance model for network meta-analysis of diagnostic test accuracy data. Stat Methods Med Res. 2018 Aug;27(8):2554-66. PMID: 29984635

Oštrbenk A, Xu L, Arbyn M, Poljak M. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework. J Clin Microbiol. 2018 Nov;56(11). PMID: 30209184

Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A. MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer. 2018 Jun 27;18(1):696. PMID: 29945565

Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Meijer CJLM, Berkhof J. Management of HPV-Positive Women in Cervical Screening Using Results from Two Consecutive Screening Rounds. Int J Cancer. 2018 Nov 22;0(ja).

Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. Eur J Health Econ. 2018 Jul 26;1-10. PMID: 30051152

Ronco G, Franceschi S. Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing. Ann Intern Med. 2018 Jan 2;168(1):75-6. PMID: 29181508

Vänskä S, Söderlund-Strand A, Uhnoo I, Lehtinen M, Dillner J. Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. Vaccine. 2018 31;36(23):3239-46. PMID: 29716776

Viti J, Poljak M, Oštrbenk A, Bhatia R, Alcañiz Boada E, Cornall AM, et al. Validation of EUROArray HPV test using the VALGENT framework. J Clin Virol. 2018 Nov;108:38-42. PMID: 30223253

Xu L, Oštrbenk A, Poljak M, Arbyn M. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework. J Clin Virol. 2018 Jan;98:37-42. PMID: 29241150

Xu L, Padalko E, Oštrbenk A, Poljak M, Arbyn M. Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework. Int J Mol Sci. 2018 Sep 11;19(9):2704. PMID: 30208597

 

Arbyn M, Redman CWE, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017;18(12):1665-79. PMID: 29126708

Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson JL, et al. Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis. Ann Intern Med. 2017 Jan 17;166(2):118-27. PMID: 27842420

Baldauf J-J, Fender M, Bergeron C, Marrer E, Velten M, Pradat P, et al. Cervical morbidity in Alsace, France: results from a regional organized cervical cancer screening program. Eur J Cancer Prev. 2017 Nov 13. PMID: 29135538

Baussano I, Diaz M, Tully S, Muñoz N, de Sanjosé S, Bosch FX, et al. Effect of age-difference between heterosexual partners on risk of cervical cancer and human papillomavirus infection. Papillomavirus Res. 2017 Jun;3:98-104. PMID: 28720465

Baussano I, Lazzarato F, Ronco G, Lehtinen M, Dillner J, Franceschi S. Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. J Infect Dis. 2017 Aug 1;216(3):336-44. PMID: 28859431

Bolatti EM, Chouhy D, Hošnjak L, Casal PE, Kocjan BJ, Bottai H, et al. Natural history of human papillomavirus infection of sun-exposed healthy skin of immunocompetent individuals over three climatic seasons and identification of HPV209, a novel betapapillomavirus. J Gen Virol. 2017 Jun;98(6):1334-48. PMID: 28590241

Elfgren K, Elfström KM, Naucler P, Arnheim-Dahlström L, Dillner J. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol. 2017 Mar;216(3):264.e1-264.e7. PMID: 27825977

Habbema D, Weinmann S, Arbyn M, Kamineni A, Williams AE, M C M de Kok I, et al. Harms of cervical cancer screening in the United States and the Netherlands. Int J Cancer. 2017 Mar 1;140(5):1215-22. PMID: 27864938

Kocjan BJ, Hošnjak L, Račnik J, Zadravec M, Bakovnik N, Cigler B, et al. Molecular characterization, prevalence and clinical relevance of Phodopus sungorus papillomavirus type 1 (PsuPV1) naturally infecting Siberian hamsters (Phodopus sungorus). J Gen Virol. 2017 Nov;98(11):2799-809. PMID: 29022861

Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017 10;8:CD008587. PMID: 28796882

Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017 02;11:CD012847. PMID: 29095502

Kyrgiou M, Kalliala I, Mitra A, Ng KYB, Raglan O, Fotopoulou C, et al. Immediate referral to colposcopy versus cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature. Int J Cancer. 2017 Jan 1;140(1):216-23. PMID: 27603593

Kyrgiou M, Kalliala IEJ, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PP, et al. Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test. Cochrane Database Syst Rev. 2017 26;1:CD009836. PMID: 28125861

Latsuzbaia A, Hebette G, Fischer M, Arbyn M, Weyers S, Vielh P, et al. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg. Diagn Cytopathol. 2017 May;45(5):384-90. PMID: 28247516

Lehtinen T, Söderlund-Strand A, Petäjä T, Eriksson T, Jokiranta S, Natunen K, et al. Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination. J Infect Dis. 2017 Nov 15;216(8):966-8. PMID: 28968844

Moriña D, de Sanjosé S, Diaz M. Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention. Sci Rep. 2017 Dec 8;7(1):17208. PMID: 29222509

Nyaga VN, Arbyn M, Aerts M. CopulaDTA: Copula Based Bivariate Beta-Binomial Models for Diagnostic Test Accuracy Studies in a Bayesian Framework. Journal of Statistical Software. 2017;82(CN1):1-27.

Polman NJ, Oštrbenk A, Xu L, Snijders PJF, Meijer CJLM, Poljak M, et al. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel. J Clin Microbiol. 2017;55(12):3544-51. PMID: 29021152

Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Meijer CJLM, Berkhof J. HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test. Br J Cancer. 2017 Nov 7;117(10):1557-61. PMID: 28881359

Prigge E-S, Arbyn M, von Knebel Doeberitz M, Reuschenbach M. Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. Int J Cancer. 2017 Mar 1;140(5):1186-98. PMID: 27859245

Qendri V, Bogaards JA, Berkhof J. Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands. J Infect Dis. 2017 15;216(2):210-9. PMID: 28586466

Ronco G, Baussano I. Causal system modelling of cervical cancer screening. The Lancet Public Health. 2017 Feb 1;2(2):e61-2. PMID: 29253393

Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, et al. Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry. Cancer Epidemiol Biomarkers Prev. 2017 Sep 8. PMID: 28887297

Šterbenc A, Hošnjak L, Chouhy D, Bolatti EM, Oštrbenk A, Seme K, et al. Molecular characterization, tissue tropism, and genetic variability of the novel Mupapillomavirus type HPV204 and phylogenetically related types HPV1 and HPV63. PLoS ONE. 2017;12(4):e0175892. PMID: 28426749

Trapero-Bertran M, Acera Pérez A, de Sanjosé S, Manresa Domínguez JM, Rodríguez Capriles D, Rodriguez Martinez A, et al. Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study. BMC Public Health. 2017 14;17(1):194. PMID: 28196467

Triglav T, Artemchuk H, Oštrbenk A, Elfström KM, Faust H, Poljak M, et al. Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. J Clin Virol. 2017;90:64-9. PMID: 28363164

van Velthoven K, Poppe W, Verschuere H, Arbyn M. Pregnancy outcome after cervical conisation: A 2nd retrospective cohort study in the Leuven University Hospital. Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:224-31. PMID: 28822944

Wentzensen N, Arbyn M. HPV-based cervical cancer screening- facts, fiction, and misperceptions. Prev Med. 2017 May;98:33-5. PMID: 28279260

 

Arbyn M, Broeck DV, Benoy I, Bogers J, Depuydt C, Praet M, et al. Surveillance of effects of HPV vaccination in Belgium. Cancer Epidemiol. 2016 Apr;41:152-8. PMID: 26895623

Arbyn M, Vanden Broeck D, Bogers J, Van Damme P, Temmerman M, Weyers S. Enrolment of young women attending cervical cancer screening to survey effectiveness of HPV vaccination. Cancer Epidemiol. 2016;45:178-9. PMID: 27847177

Arbyn M, Xu L, Wentzensen N. Reply to HPV test results provide useful risk stratification information in women with ASC-H Pap test findings. Cancer Cytopathol. 2016;124(10):754-5. PMID: 27336222

Baussano I, Lazzarato F, Brisson M, Franceschi S. Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior. Emerging Infect Dis. 2016 Jan;22(1):18-23. PMID: 26691673

Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016 Feb;13(2):119-32. PMID: 26323382

Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016 Nov;1(1):e8-17. PMID: 29253379

Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M. HPV testing in the context of post-treatment follow up (test of cure). J Clin Virol. 2016 Mar;76 Suppl 1:S56-61. PMID: 26525202

Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Broeck DV, et al. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol. 2016 Sep 1;54(9):2337-42. PMID: 27385707

De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, et al. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol. 2016;141(2):341-7. PMID: 26921784

Dijkstra MG, Zummeren M van, Rozendaal L, Kemenade FJ van, Helmerhorst TJM, Snijders PJF, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016 Oct 4;355:i4924. PMID: 27702796

Elfström KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016 Jan 15;213(2):199-205. PMID: 26142436

Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. BMC Public Health. 2016 Feb 19;16:172. PMID: 26895838

Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M. Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. J Clin Virol. 2016;81:6-11. PMID: 27262102

Jelen MM, Chen Z, Kocjan BJ, Hošnjak L, Burt FJ, Chan PKS, et al. Global genomic diversity of human papillomavirus type 11 (HPV11) based on 433 isolates and 78 complete genome sequences. J Virol. 2016 Mar 30;JVI.03149-15. PMID: 27030261

Jentschke M, Chen K, Arbyn M, Hertel B, Noskowicz M, Soergel P, et al. Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections. J Clin Virol. 2016;82:46-50. PMID: 27434147

Kocjan BJ, Hošnjak L, Poljak M. Detection of alpha human papillomaviruses in archival formalin-fixed, paraffin-embedded (FFPE) tissue specimens. J Clin Virol. 2016 Mar;76 Suppl 1:S88-97. PMID: 26514313

Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016 Jul 28;354:i3633. PMID: 27469988

Latsuzbaia A, Tapp J, Nguyen T, Fischer M, Arbyn M, Weyers S, et al. Analytical performance evaluation of Anyplex II HPV28 and Euroarray HPV for genotyping of cervical samples. Diagn Microbiol Infect Dis. 2016 Jul;85(3):318-22. PMID: 27156793

Luttmer R, De Strooper LMA, Berkhof J, Snijders PJF, Dijkstra MG, Uijterwaal MH, et al. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). Int J Cancer. 2016;138(4):992-1002. PMID: 26317579

Luttmer R, De Strooper LMA, Dijkstra MG, Berkhof J, Snijders PJF, Steenbergen RDM, et al. FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Cancer. 2016 Aug 23;115(5):579-87. PMID: 27415009

Luttmer R, Dijkstra MG, Snijders PJF, Berkhof J, van Kemenade FJ, Rozendaal L, et al. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol. 2016;29(8):870-8. PMID: 27150161

Nyaga V, Aerts M, Arbyn M. ANOVA model for network meta-analysis of diagnostic test accuracy data. arXiv:160402018 [stat]. 2016 Apr 7.

Poljak M, Ginocchio CC. Editorial: Recent Advances in Molecular Detection of Human Papillomavirus and Cervical Cancer Screening. J Clin Virol. 2016 Mar 1;76:S1-2. PMID: 26597652

Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016 Mar;76 Suppl 1:S3-13. PMID: 26601820

Poljak M, Oštrbenk A, Seme K, Šterbenc A, Jančar N, Vrtačnik Bokal E. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting. J Clin Virol. 2016 Mar;76 Suppl 1:S29-39. PMID: 26643051

Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M, et al. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. Eur J Cancer. 2016 Nov 1;68:148-55. PMID: 27755998

Rossi PG, Ronco G, Dillner J, Elfström KM, Snijders PJF, Arbyn M, et al. Why follow-back studies should be interpreted cautiously: The case of an HPV-negative cervical lesion. Cancer Cytopathol. 2016 Jan;124(1):66-7. PMID: 26356132

Santesso N, Mustafa RA, Schünemann HJ, Arbyn M, Blumenthal PD, Cain J, et al. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet. 2016 Mar;132(3):252-8. PMID: 26868062

Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open. 2016 Apr 1;6(4):e010660. PMID: 27113237

Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veerus P, Plummer M, et al. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study. Lancet Oncol. 2016 Oct;17(10):1445-52. PMID: 27567054

Verdoodt F, Jiang X, Williams M, Schnatz PF, Arbyn M. High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis. Int J Cancer. 2016 Jan 15;138(2):303-10. PMID: 25583258

Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016 Mar;76 Suppl 1:S49-55. PMID: 26643050

Xu L, Verdoodt F, Wentzensen N, Bergeron C, Arbyn M. Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer. Cancer Cytopathol. 2016 Apr;124(4):261-72. PMID: 26618614

 

Arbyn M, Castle PE. Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program. Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):769-72. PMID: 25713024

Arbyn M, Fabri V, Temmerman M, Simoens C. Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006). PLoS ONE. 2014;9(4):e92615. PMID: 24690620

Arbyn M, Haelens A, Desomer A, Verdoodt F, Thiry N, Francart J, et al. Cervical cancer screening program and human papillomavirus (HPV) testing, part II: update on HPV primary screening. Brussels: Belgian Health Care Knowledge Centre (KCE); 2015. Report No.: KCE Reports  238Cs. D/2015/10.273/16.

Arbyn M, Kyrgiou M, Gondry J, Petry KU, Paraskevaidis E. Long term outcomes for women treated for cervical precancer. BMJ. 2014;348:f7700. PMID: 24423750

Arbyn M, Snijders PJF, Meijer CJLM, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015 Sep;21(9):817-26. PMID: 25936581

Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014 Dec;234(4):431-5. PMID: 25124771

Arbyn M, Verdoodt F, Cuschieri K. Reply to triage of women with minor abnormal cervical cytology: Meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2014d Jan;122(1):77-8. PMID: 24170382

Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014e Feb;15(1474-5488 (Electronic)):172-83. PMID: 24433684

Baussano I, Dillner J, Lazzarato F, Ronco G, Franceschi S. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect Agents Cancer. 2014;9(1):4. PMID: 24438317

Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, et al. Informed Cytology for Triaging HPV-Positive Women: Substudy Nested in the NTCC Randomized Controlled Trial. J Natl Cancer Inst. 2015 Jan 7;107(2). PMID: 25568167

Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, et al. The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer. 2015 Jun 15;136(12):2741-51. PMID: 24740700

Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJLM, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016. PMID: 25985328

Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework. J Clin Microbiol. 2015 Oct;53(10):3272-9. PMID: 26246482

Elfström KM, Dillner J, Arnheim-Dahlström L. Organization and quality of HPV vaccination programs in Europe. Vaccine. 2015 Mar 30;33(14):1673-81. PMID: 25720792

Elfström KM, Smelov V, Johansson ALV, Eklund C, Nauclér P, Arnheim-Dahlström L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014 Jan 16;348:g130. PMID: 24435414

Elfström KM, Smelov V, Johansson ALV, Eklund C, Naucler P, Arnheim-Dahlström L, et al. Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer. 2015 Jan 15;136(2):350-9. PMID: 24842156

Feoli F, Renard C, Abouyahia M, De Wind R, Larsimont D, Arbyn M. Retrospective Rescreening of Negative Cervical Cytology Samples Preceding Histologically Proven CIN2-3 and Squamous Cell Carcinoma: An Educational Opportunity to Understand and Prevent Laboratory Errors. Acta Cytol. 2015;59(3):265-72. PMID: 26279075

Franceschi S, Baussano I. Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era. J Infect Dis. 2014 Aug 15;210(4):507-9. PMID: 24610878

Geraets DT, Cuschieri K, de Koning MNC, van Doorn LJ, Snijders PJF, Meijer CJLM, et al. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol. 2014 Nov;52(11):3996-4002. PMID: 25210073

Giorgi-Rossi P, Arbyn M, Meijer CJLM. Cervical cancer screening by human papillomavirus testing followed by cytology triage. JAMA Intern Med. 2015 Jun;175(6):1068. PMID: 26030858

Ibáñez R, Alejo M, Combalia N, Tarroch X, Autonell J, Codina L, et al. Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. Biomed Res Int. 2015;2015:605375. PMID: 26180804

von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015 Dec 1;1:22-31.

Kocjan BJ, Bzhalava D, Forslund O, Dillner J, Poljak M. Molecular methods for identification and characterization of novel papillomaviruses. Clin Microbiol Infect. 2015 Sep;21(9):808-16. PMID: 26003284

Kocjan BJ, Šterbenc A, Hošnjak L, Chouhy D, Bolatti E, Giri AA, et al. Genome announcement: complete genome sequence of a novel Mupapillomavirus, HPV204. Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(2):21-3. PMID: 26086163

Kyrgiou M, Arbyn M, Paraskevaidis E. Pregnancy outcomes following cold coagulation for CIN have not yet been reported. BJOG. 2014;121(8):941-2.

Kyrgiou M, Mitra A, Arbyn M, Paraskevaidi M, Athanasiou A, Martin-Hirsch PPL, et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2015 Sep 29;(9):CD008478. PMID: 26417855

Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014 Oct 28;349:g6192. PMID: 25352501

Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine. 2015 Mar 3;33(10):1284-90. PMID: 25593103

Meijer CJLM, Snijders PJF. Cervical cancer in 2013: Screening comes of age and treatment progress continues. Nat Rev Clin Oncol. 2014 Feb;11(2):77-8. PMID: 24445518

Merckx M, Vanden Broeck D, Benoy I, Depuydt C, Weyers S, Arbyn M. Early effects of human papillomavirus vaccination in Belgium. Eur J Cancer Prev. 2015 Jul;24(4):340-2. PMID: 25117724

Moss EL, Redman CWE, Arbyn M, Dollery E, Petry KU, Nieminen P, et al. Colposcopy training and assessment across the member countries of the European Federation for Colposcopy. Eur J Obstet Gynecol Reprod Biol. 2015 May;188:124-8. PMID: 25839437

Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16(INK4a) detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014 Nov;15(12):1319-31. PMID: 25439690

Nowakowski A, Cybulski M, Śliwczyński A, Chil A, Teter Z, Seroczyński P, et al. The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines. BMC Cancer. 2015 Apr 14;15:279. PMID: 25879466

Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39. PMID: 25810908

Nyaga VN, Arbyn M, Aerts M. METAPROP: Stata module to perform fixed and random effects meta-analysis of proportions. Boston College Department of Economics; 2014. (Statistical Software Components).

Östensson E, Alder S, Elfström KM, Sundström K, Zethraeus N, Arbyn M, et al. Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years. PLoS ONE. 2015;10(5):e0128270. PMID: 26011051

Oštrbenk A, Kocjan BJ, Hošnjak L, Li J, Deng Q, Šterbenc A, et al. Identification of a Novel Human Papillomavirus, Type HPV199, Isolated from a Nasopharynx and Anal Canal, and Complete Genomic Characterization of Papillomavirus Species Gamma-12. PLoS ONE. 2015;10(9):e0138628. PMID: 26375679

Poljak M. Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening. Clin Microbiol Infect. 2015 Sep 1;21(9):806-7. PMID: 26068650

Reuschenbach M, Wentzensen N, Dijkstra MG, Doeberitz M von K, Arbyn M. p16INK4a Immunohistochemistry in Cervical Biopsy Specimens A Systematic Review and Meta-Analysis of the Interobserver Agreement. AJCP. 2014 Dec 1;142(6):767-72. PMID: 25389329

Siebers AG, Arbyn M, Melchers WJG, van Kemenade FJ, Vedder JEM, van der Linden H, et al. Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study. Cancer Causes Control. 2014 Sep;25(9):1141-9. PMID: 24935226

Smelov V, Elfström KM, Johansson ALV, Eklund C, Naucler P, Arnheim-Dahlström L, et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer. 2015 Mar 1;136(5):1171-80. PMID: 25043476

Steenbergen RDM, Snijders PJF, Heideman DAM, Meijer CJLM. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014 Jun;14(6):395-405. PMID: 24854082

Veldhuijzen NJ, Berkhof J, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, et al. The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):111-8. PMID: 25300476

Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJF, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015 Nov;51(16):2375-85. PMID: 26296294

Vink MA, Bogaards JA, Meijer CJLM, Berkhof J. Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended? Int J Cancer. 2015 Jul 15;137(2):420-7. PMID: 25484263

 

European Union’s Seventh Framework Programme

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no FP7-F3-2013-603019.


Copyright © 2018 ICO/IARC Information Centre on HPV and Cancer | Disclaimer | Contact | RSS